Wechalekar, AD;
Fontana, M;
Quarta, CC;
Liedtke, M;
(2022)
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review.
JACC: CardioOncology
, 4
(4)
pp. 427-441.
10.1016/j.jaccao.2022.08.009.
Preview |
PDF
1-s2.0-S266608732200391X-main.pdf - Published Version Download (2MB) | Preview |
Abstract
Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of cardiomyopathy are common presenting features, and patients often are referred to cardiologists. Cardiac amyloid infiltration is the leading predictor of death. However, the variable presentation and perceived rarity of the disease frequently lead to delay in suspecting amyloidosis as a cause of heart failure, leading to misdiagnoses and a marked delay in diagnosis, with devastating consequences for the patient. A median time from symptom onset to correct diagnosis of about 2 years is often too long when median survival from diagnosis for patients with AL amyloidosis and cardiomyopathy is 4 months to 2 years. The authors highlight the challenges to diagnosis, identify gaps in the current knowledge, and summarize novel treatments on the horizon to raise awareness about the critical need for early recognition of symptoms and diagnosis of AL amyloidosis aimed at accelerating treatment and improving outcomes for patients.
| Type: | Article |
|---|---|
| Title: | AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jaccao.2022.08.009 |
| Publisher version: | https://doi.org/10.1016/j.jaccao.2022.08.009 |
| Language: | English |
| Additional information: | ©2022 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FO UNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE ( http://creativecommons.o rg/licenses/by-nc-nd/4.0/ ) . |
| Keywords: | AL amyloidosis, awareness, diagnosis, future therapies |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10160964 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
